Harold Ross Roberts

Harold Ross Roberts's AcademicInfluence.com Rankings

Harold Ross Roberts

Philosophy

#8679

World Rank

#12103

Historical Rank

Ontology

#102

World Rank

#115

Historical Rank

Logic

#5708

World Rank

#7129

Historical Rank

philosophy Degrees

Harold Ross Roberts

Biology

#11791

World Rank

#15215

Historical Rank

Biochemistry

#1969

World Rank

#2110

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Harold Ross Roberts's Degrees

PhD Biochemistry University of California, Berkeley
Doctorate Medicine Stanford University

Why Is Harold Ross Roberts Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Harold Ross Roberts's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Platelets and thrombin generation. (2002) (621)
Platelet activity of high‐dose factor VIIa is independent of tissue factor (1997) (579)
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. (1998) (275)
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa (1994) (269)
The use of recombinant factor VIIa in the treatment of bleeding disorders. (2004) (266)
A cell-based model of thrombin generation. (2006) (228)
Clinical experience with recombinant factor VIIa. (1998) (217)
Thrombin activates factor XI on activated platelets in the absence of factor XII. (1999) (202)
Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. (1980) (188)
Safety profile of recombinant factor VIIa. (2004) (180)
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. (1995) (175)
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. (2003) (159)
High‐dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia‐like conditions in a cell‐based model system (2001) (153)
Transmission of a procoagulant signal from tissue factor‐bearing cells to platelets (1996) (149)
Current concepts of hemostasis: implications for therapy. (2004) (141)
The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. (1989) (139)
High dose factor VIIa improves clot structure and stability in a model of haemophilia B (2005) (131)
The liver and blood coagulation: physiology and pathology. (1972) (130)
Thrombogenic materials in prothrombin complex concentrates. (1974) (129)
Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. (1999) (128)
Newer concepts of blood coagulation (1998) (119)
Platelet procoagulant complex assembly in a tissue factor‐initiated system (1994) (116)
A possible mechanism of action of activated factor VII independent of tissue factor. (1998) (112)
Cutaneous wound healing is impaired in hemophilia B. (2006) (111)
The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. (2000) (107)
Molecular Basis of Thrombosis and Hemostasis (1995) (105)
Recombinant factor VIIa (Novoseven) and the safety of treatment. (2001) (103)
Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. (1976) (99)
Clinical experience with activated factor VII: focus on safety aspects. (1998) (97)
Genetic variants of hemophilia B: detection by means of a specific PTC inhibitor. (1968) (97)
A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. (1968) (96)
Secondary prophylaxis with recombinant activated factor VII improves health‐related quality of life of haemophilia patients with inhibitors (2008) (95)
Intravascular coagulation with use of human prothrombin complex concentrates. (1976) (93)
Platelet Heterogeneity: Variation in Coagulation Complexes on Platelet Subpopulations (2005) (92)
Rationale for the use of high dose rFVIIa in a high‐titre inhibitor patient with haemophilia B during major orthopaedic procedures (2001) (86)
Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. (1989) (85)
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. (1998) (84)
Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX. (1985) (81)
Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. (1966) (81)
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. (2002) (79)
Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. (1994) (79)
Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? (2005) (78)
Continuous Intravenous Infusion of Factor VIII in Classic Haemophilia (1970) (74)
Treatment of Anti-Factor VIII Antibodies (1977) (73)
Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor (1989) (71)
Congenital deficiency of blood clotting factors II, VII, IX, and X. (1979) (66)
Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study (1993) (66)
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. (1994) (65)
TFPIβ, a Second Product from the Mouse Tissue Factor Pathway Inhibitor (TFPI) Gene (1999) (63)
A Clinical and Experimental Study of Acquired Inhibitors to Factor VIII (1965) (63)
Cellular interactions in hemostasis. (1996) (57)
A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects (2005) (56)
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). (1990) (55)
Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. (2002) (55)
Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. (1990) (54)
Liver biopsy in hemophilia A. (1977) (52)
The dysfibrinogenaemias (2001) (52)
CLINICAL USE OF A NEW GLYCINE‐PRECIPITATED ANTIHEMOPHILIC FRACTION (1965) (52)
Factor IXAlabama: a point mutation in a clotting protein results in hemophilia B. (1987) (50)
The genetic heterogeneity of hemophilia B. (1970) (50)
Platelet-dependent action of high-dose factor VIIa. (2002) (48)
Current management of hemophilia B. (1993) (48)
Manipulation of prothrombin concentration improves response to high‐dose factor VIIa in a cell‐based model of haemophilia (2006) (47)
The use of high-dose intravenous γ-globulin in acquired von Willebrand syndrome (1988) (46)
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. (2002) (44)
Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. (1985) (44)
A rapid method to isolate platelets from human blood by density gradient centrifugation. (1992) (43)
Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case. (1983) (41)
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. (1997) (39)
The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell‐based model of coagulation (2000) (39)
New perspectives on the coagulation cascade. (1992) (38)
Monitoring coagulation and the clinical effects of recombinant factor VIIa. (2004) (38)
Chronic hepatitis in patients with hemophilia A: histologic studies in patients with intermittently abnormal liver function tests. (1982) (38)
Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. (1992) (37)
Summary Report and Recommendations of the Task Force Members and Consultants (1975) (37)
Release of Factor VIII (Antihaemophilic Factor) from Perfused Organs and Tissues (1967) (36)
FAMILIAL PROTEIN S DEFICIENCY WITH A VARIANT PROTEIN S MOLECULE IN PLASMA AND PLATELETS (1989) (36)
Deencryption of cellular tissue factor is independent of its cytoplasmic domain. (2000) (36)
Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. (2003) (35)
Factor VIII inhibitors: A clinical overview (1982) (35)
Immunochemical characterization of a monoclonal G4,lambda human antibody to factor IX. (1972) (34)
ACQUIRED INHIBITORS OF PLASMA FACTOR IX A STUDY OF THEIR INDUCTION, PROPERTIES AND NEUTRALIZATION (1966) (33)
Hemorrhagic states secondary to intravascular clotting: an experimental study of their evolution and prevention. (1958) (33)
Structure and function of factor IX: defects in haemophilia B. (1985) (32)
Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. (2008) (30)
Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. (1989) (28)
Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. (1981) (27)
Overview of anticoagulant drugs for the future. (2002) (27)
Survival of Transfused Factor X in Patients with Stuart Disease (1965) (27)
Hemophiliacs with inhibitors: therapeutic options. (1981) (27)
HEMOSTASIS IN FACTOR V DEFICIENCY (1964) (26)
Inhibitors in Christmas disease. (1984) (25)
Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill. (1978) (25)
An acquired inhibitor to factor XIII. (1972) (25)
Dominant inheritance of hemophilia A in three generations of women. (1975) (24)
Hemolysis caused by factor VIII concentrates. (1976) (24)
Oscar ratnoff: his contributions to the golden era of coagulation research (2003) (23)
Heterozygosity and Homozygosity in von Willebrand's Disease.∗ (1965) (22)
Overview of inhibitors to factor VIII and IX. (1984) (22)
Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases. (1988) (22)
The treatment of hemophilia: past tragedy and future promise. (1989) (22)
The Treatment of Factor VIII Inhibitors ‐ A General Overview (1996) (22)
Purification and Characterization of an Abnormal Factor IX (Christmas Factor) Molecule (1978) (21)
Hageman trait (factor XII deficiency): a probably second genotype inherited as an autosomal dominant characteristic. (1972) (20)
The Procoagulant Activity of Granulocytes 1 (1973) (20)
Detection of Genetic Variants of Haemophilia B with an Immunosorbent Technique (1973) (20)
Immunochemical characterization of a polyclonal human antibody to factor IX. (1977) (20)
Immunochemical characterization of a human antibody to factor XIII. (1973) (18)
The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. (1998) (18)
Predisposition to intravascular coagulation. (1966) (18)
Dental care of patients with hereditary disorders of blood coagulation. (1968) (17)
The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. (1988) (17)
Content of Tissue Activator of Plasminogen in Monkey Tissues (1957) (17)
Uncertain times for research on hemophilia and allied disorders (2005) (17)
THE INHERITANCE OF STUART DISEASE: INVESTIGATION OF A FAMILY WITH FACTOR X DEFICIENCY' (1965) (16)
Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B (1990) (16)
Less Common Congenital Disorders of Hemostasis (2013) (16)
Covert intravascular clotting. (1965) (16)
Recombinant factor VIIa: a general hemostatic agent? Yes (2004) (15)
Post-transfusion Hepatitis Following the Use of Prothrombin Complex Concentrates (1975) (15)
Studies of the Antihemophilic Factor (AHF, Factor VIII) Produced in von Willebrand's Disease.∗ (1964) (15)
Medical complications of hemophilia. (1980) (14)
Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. (1990) (14)
THE PLATELET MEMBRANE AS A CATALYTIC SURFACE IN THROMBIN GENERATION: AVAILABILITY OF PLATELET FACTOR 1 AND PLATELET FACTOR 3 * (1981) (14)
The Use of Agents that By–Pass Factor VIII Inhibitors in Patients with Haemophilia (1999) (14)
Use of plasma exchange in hereditary deficiency of factor V and factor VIII (1996) (14)
Mammalian recombinant coagulation proteins: structure and function. (1998) (13)
Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules. (1990) (13)
Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. (1989) (13)
Platelet activation in patients with thrombotic thrombocytopenic purpura (1993) (11)
Spontaneous antithrombin in a patient with benign paraprotein (1987) (11)
Thrombolysis and Thrombolytic Agents: A Brief Review (1961) (11)
Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction (1980) (11)
Hemostasis and Thrombosis: Practical Guidelines in Clinical Management (2014) (10)
Cloning, Expression, and Characterization of Mouse Tissue Factor Pathway Inhibitor (TFPI) (1998) (10)
Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. (1986) (10)
Hemophilia care in the 21st century. (2004) (10)
Glycine-precipitated antihemophilic factor concentrates and their clinical use. (1968) (9)
Recombinant factor VIIa: how safeis the stuff? (2005) (9)
Possible implications of the autosomal and X-linked hemophilia phenotypes. (1965) (9)
Use of an immunosorbent technique in the study of a PTC inhibitor: a new method for the investigation of blood coagulation. (1965) (9)
INTENSIVE PLASMA THERAPY IN THE HEMOPHILIAS. (1964) (8)
The factor VIII peptide consisting of amino acids 698 to 712 enhances factor IXa cleavage of factor X (1997) (8)
Prothrombin complex concentrates (1978) (7)
Fathers of modern coagulation (2007) (7)
Progressive improvement in wound healing with increased therapy in haemophilia B mice (2013) (7)
Gene therapy for hemophilia: a step closer to reality. (2000) (7)
Panel discussion on the treatment of patients with factor VIII inhibitors. (1984) (7)
A simple assay for human factor IX: use of canine hemophilia B plasma as substrate. (1978) (7)
Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources (1993) (7)
Factor XI deficiency, juvenile rheumatoid arthritis and systemic lupus erythematosus. Report of the first case. (1977) (7)
Vitamin K supplementation during oral anticoagulation: cautions (2007) (6)
Structural abnormalities of the vitamin K-dependent clotting factors. (1981) (6)
Haemophilia and Haemostasis: A Case-Based Approach to Management (2007) (6)
Calcium ion binding to human and bovine factor X. (1990) (6)
Platelets : their role in hemostasis and thrombosis : transactions of the conference held under the auspices of the International Committee on Haemostasis and Thrombosis, Chapel Hill, North Carolina, U.S.A., December 1966 (1967) (5)
Treatment of Bleeding and Thrombotic Disorders (2001) (5)
Treatment of busulfan-induced pancytopenia. (1976) (5)
Novel therapeutic agents in the management of hemorrhage and thrombosis. (2006) (5)
Elevation of factor 8 in hypercoagulable states. (1966) (5)
Acquired inhibitors to factor IX. (1970) (4)
Proceedings of the Conference on thrombolytic agents, April 8-9, 1960 Chicago, Illinois (1960) (4)
The statistics of nutrition sampling and analysis. (1974) (4)
Gene therapy for hemophilia? (2005) (4)
Vitamin K supplementation during oral anticoagulation: concerns. (2007) (4)
Genetic Variants of Hemophilia B. (1977) (4)
Intravascular clotting: focal and systemic. (1964) (4)
Letter: Isoniazid and disseminated intravascular coagulation. (1976) (4)
Characterization of the Clotting Activities of Structurally Different Forms of Activated Factor IX Enzymatic Properties of Normal Human Factor IXaae, Factor lXaB, and Activated Factor lXChapol Hill (3)
Choice of replacement therapy for hemophilia (2003) (3)
Recombinant human factor VIII (1990) (3)
An Agarose Plate Method for Detecting Alloantisera to Coagulant Factor IX and Factor IX Antigen (1980) (3)
Induction of immune tolerance to factor VIII: a plea for caution. (1988) (3)
Isolation and characterization of granulocyte lysosomal proteins and study of their effects on the clotting system (1979) (3)
Future developments in the treatment of haemophilia B (1995) (3)
Immunochemical Characterization of a Factor IX Inhibitor Following Anamnestic Response (1975) (3)
Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction. (1980) (3)
Dental treatment of patients with hemorrhagic disorders. (1970) (3)
Secondary Prophylaxis with rFVIIa Improves Quality of Life of Hemophilia Patients with Inhibitors and Frequent Bleeds. (2006) (3)
Chapter 5 – Less Common Congenital Disorders of Hemostasis (2007) (2)
Further studies of in vivo complementation in hemophilia. (1966) (2)
hemophilia B Factor IXAlabama: a point mutation in a clotting protein results in (2011) (2)
Thrombin Biology in the 21st Century (2006) (2)
Haemostatic Failure of Prothrombin Complex Concentrates during Elective Dental Procedure (1979) (2)
Blood coagulation and hemophilioid disorders. (1968) (2)
Reply: Hypercoagulable States (1997) (2)
Binding of Allo- and Heteroantibodies to Human Factor IX (F. IX) (1979) (2)
Vitamin K supplementation during oral anticoagulation : cautions. Authors' reply (2007) (2)
Highly purified factor VIII concentrates. (1990) (2)
Haemostatic failure of prothrombin complex concentrates during elective dental procedure. (1980) (2)
Other Issues in Hemophilia Care (2012) (1)
Management during Procedures (2012) (1)
Contributions to the evolution of knowledge about hereditary hemorrhagic disorders (2007) (1)
Some determinants of the disappearance of transfused factor X. (1965) (1)
Factor IX Deficiency or Hemophilia B: Clinical Manifestations and Management (2014) (1)
Nontoxic Irreversible Inhibitors of Factors IXa, Xa, and Thrombin: Potential Therapeutic Agents for the in Vivo Regulation of Thrombin Generation and Activity a (1986) (1)
10th Novo Nordisk Symposium on Haemostasis Management – Introduction (2010) (1)
Clinical Trials of Recombinant Factor VIII (1991) (1)
Use of aliphatic amino acid precipitated antihemophilic factor in therapy of hemophilia. (1968) (1)
Isolation and Characterization of Factor IX Chapel Hill (1978) (1)
Overview and research opportunities (1992) (1)
Subject Index, Vol. 26 (suppl 1), 1996 (1996) (1)
More information on patients with factor XI deficiency. (2004) (1)
Proposed symbols for factor VIII and von Willebrand factor. (1986) (1)
COAT Platelet Formation Is P2Y12-Dependent. (2004) (1)
Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. (1997) (1)
New aspects of haemophilia treatment : 3rd Symposium, September 21-23, 1995, Copenhagen, Denmark (1996) (1)
At the end of the first 3 years (2007) (1)
Release of factor 8 (antihaemophilic factor) from perfused organs and tissues. (1967) (1)
wounding: implications for bleeding in hemophilia Perivascular tissue factor is down-regulated following cutaneous (2008) (1)
Coagulation training for pathology residents: a patient care experience. (1980) (0)
Restoring Initial Thrombin Generation Does Not Normalize Cutaneous Wound Healing in Hemophilia B. (2006) (0)
RESTORING INITIAL THROMBIN GENERATION DOES NOT NORMALIZE CUTANEOUS WOUND HEALING IN HEMOPHILIA B (2007) (0)
Letter: Platelet-function tests: predictive value. (1975) (0)
Tissue Factor Is Absent from Sites of Cutaneous Wounds: Implications for Bleeding in Hemophilia. (2006) (0)
Factor XI Deficiency, Juvenile Rheumatoid Arthritis (JRA), and Systemic Lupus Erythematosus (SLE) : Report of the First Case (1975) (0)
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. (1983) (0)
Treatment of bleeding and thrombotic disorders: Introduction (2001) (0)
PREVENTION OF DEEP VENOUS THROMBOSIS: CONCLUSIONS OF A CONSENSUS DEVELOPMENT CONFERENCE (1987) (0)
in Three Generations of Women (2017) (0)
Hemolysis After Factor VIII Administration-Reply (1977) (0)
In Memoriam: Kenneth M. Brinkhous (1908–2000) (2001) (0)
to Factor IX Human Antibody λ G4, γ Immunochemical Characterization of a Monoclonal (2013) (0)
Human Antibody to Factor (0)
New Aspects of Haemophilia Treatment: 3rd Symposium, Copenhagen, September 1995 (1996) (0)
Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX. (1977) (0)
International units for tissue plasminogen activator. (1986) (0)
Gla domain mutants in vivo Circulating and binding characteristics of wild-type factor IX and certain (2013) (0)
A clinical and experimental study of acquired inhibitors to factor 8. (1965) (0)
GENE THERAPY FOR HAEMOPHILIA A: A WORK IN PROGRESS. SYMPOSIUM (1998) (0)
Ipver Biopsy in Hemophilia A (0)
Carboxyterminal Cleavage Site of the Activation Peptide (2013) (0)
Prothrombin times on deficient plasma reconstituted with factors IX and X (1994) (0)
A SIWLC ASSAY FOR HUMt\N FACTOR IX: USE OF CANINE HEMOPHILLA B PLASM AS SUBSTUTE (1977) (0)
Proceedings of the National Heart, Lung, and Blood Institute Workshop on Hemostasis, Thrombosis, and Cardiovascular Diseases. Overview and research opportunities. (1992) (0)
ISTH and SSC MEETINGS Second Announcement of the XVIth Congress of the ISTH (2010) (0)
Hemophilia and hemostasis (2015) (0)
A Radioimmunoassay for Factor IX (F. IX) Using Staph A (1979) (0)
Kenneth M. Brinkhous (2001) (0)
Clinical Role of Recombinant Factor Vlla in Bleeding Disorders (2008) (0)
Treatment for Other Conditions (2012) (0)
Rare Platelet and Coagulation Disorders (2007) (0)
Comprar Haemophilia and Haemostasis: A Case-based Approach to Management | Todor N. Mazgalev, Ph.D | 9781405167161 | Wiley (2009) (0)
Hemophilia with Inhibitors (2012) (0)
Acquired Bleeding Diatheses (2007) (0)
Title Page / Table of Contents, Vol. 26, Supplement 1, 1996 (1996) (0)
Hemophilia and Hemostasis: A Case-Based Approach to Management: Second Edition (2012) (0)
Current Concepts of HemostasisImplications for Therapy (2004) (0)
Factor VIII replacement therapy. Issues and future prospects. (1991) (0)
CLINICAL CONCEPTS AND COMMENTARY (2004) (0)
Other Bleeding Disorders (2012) (0)
BUYERS' GUIDE EDITION. LABORATORY INTERNET DIRECTORY (1997) (0)
Rare Forms of von Willebrand Disease (2012) (0)
Mutant forms of Factor IX (1977) (0)
Article Title: Elevated Prothrombin Results in Clots with an Altered Fiber Structure: a Possible Mechanism of the Increased Thrombotic Risk Running title: Elevated prothrombin alters clot structure (2002) (0)
The biology of haemostasis and thrombosis (2020) (0)
A Clinical and Experimental Study of Acquired Inhibitors to Factor (0)
possible mechanism of the increased thrombotic risk Elevated prothrombin results in clots with an altered fiber structure: a (2013) (0)
A comparison of the European Accord and the Recommendations of the American National Hemophilia Foundation (1994) (0)
Hemophilic Treatment for Procedures (2012) (0)
BINDING OF CALCIUM TO HUMAN AND BOVINE FACTOR X (1987) (0)
Kenneth M. Brinkhous: Investigator, Teacher, Administrator, and Gene Therapist (2001) (0)
Haemophilia A and Haemophilia B (2007) (0)
G(enctic Variants of Hemophilia B: Detctioaln b Means of a Specific PTC Inhibitor (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Harold Ross Roberts?

Harold Ross Roberts is affiliated with the following schools:

Harold Ross Roberts's Academic­Influence.com Rankings

Harold Ross Roberts's Degrees

Why Is Harold Ross Roberts Influential?

Harold Ross Roberts's Published Works

Published Works

What Schools Are Affiliated With Harold Ross Roberts?

Harold Ross Roberts's AcademicInfluence.com Rankings